Abstract:
Hepatitis B remains a significant risk to patients and staff members of hemodialysis unit. Prior to immunization, 38 hemodialysis patients and 24 staff members were screened for HBs antigen, HBc antibodies and HBs antibodies using ELISA method (Abbott). Of 18 (47%) patients, five were chronic carriers of HBsAg and 13 had anti-HBs and anti-HBc while anti-HBs and anti-HBc were found in four (17%) members of medical staff. A total of 20 (53%) susceptible patients (mean 51.2 years) and 19 (79%) susceptible staff members (mean 28.1 years) received hepatitis B vaccine (H-B-VAX, Merck, Sharp and Dohme). Between patients were four (20%) non-responders and seven (35%) low-responders while among medical staff were two (10.5%) non-responders and one (5.2%) low responder only. The geometric mean titer of anti-HBs was 724 IU/L in patients and 3407 IU/L in staff members. Non-responders (5 of 6) who were given a fourth vaccine dose also failed to mount an antibody response. In none of vaccinated patients antibody to human immunodeficiency virus (HIV-1) occurred in their sera three and six months after complete vaccination. Consideration should be given to a prevaccinal screening of presumptive vaccinees between patients and staff members of hemodialysis units because of high level of preexisting HBV infection among them. The data suggest a high non-responder and low-responder rate in vaccinated hemodialysis patients and serial surveillance for anti-HBs is warranted especially in persons aged over 40 years. Additional booster dose or some doses of HB vaccine should be given to low-responders and they should be retested thereafter. Non-responders still remain the unresolved problem.
Keywords: Adult Aged English Abstract Female *Health Manpower *Hemodialysis/ADVERSE EFFECTS Hepatitis B/PREVENTION & CONTROL Hepatitis B Antibodies/ANALYSIS Hepatitis B Core Antigens/IMMUNOLOGY Hepatitis B Surface Antigens/ANALYSIS/IMMUNOLOGY Human Male Middle Age Occupational Diseases/PREVENTION & CONTROL Viral Hepatitis Vaccines/*IMMUNOLOGY JOURNAL ARTICLE 900830
M9080710
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.
